Münster, Germany, December 18, 2015: German based biotech company CILIAN AG reports positive in vivo results for its seasonal sub-unit flu vaccine, CiFlu®. Immunogenicity studies were conducted in non-human primates. In collaboration with CILIAN’s scientific partners within the European ADITEC consortium, a quadrivalent seasonal flu vaccine was tested at the facilities of CEA’s Division of Immuno-Virology in Fontenay-aux-Roses, France. The tested vaccine contained recombinant hemagglutinin of two A-strains and two B-strains.
Significant and strong immunogenicity measured with a standardized hemagglutination inhibition (HI) test was achieved and seroconversion occurred in the primates. Non-human primates are an in vivo model closest to humans. Results usually seen in this model are considered indicative of efficacy expected in clinical trials in humans. Results seen by CILIAN in primates confirm results already seen in a number of other pre-clinical studies conducted with CiFlu®. This is further evidence that CiFlu® is an effective, fully recombinant, none egg-based sub-unit flu vaccine without adjuvant or other impurities.
CiFlu® is manufactured using CILIAN’s proprietary CIPEX protein expression system. CIPEX uses a single cell organism, Tetrahymena thermophila. This expression system produces a very robust protein in a safe, fast and significantly less expensive process as compared to egg-based systems.
About CILIAN
CILIAN AG is a privately owned biotechnology company located in Münster, Germany. CILIAN develops recombinant sub-unit vaccines; therapeutic enzymes for the treatment of pancreatic insufficiency; and ADCC monoclonal antibodies against cancer utilizing its proprietary protein expression system CIPEX. For more information on CILIAN AG, please go to www.cilian.com.
CILIAN is an affiliated member of ADITEC and participates in its advanced immunization technologies research program. CiFlu® is a registered trademark of CILIAN AG in the European Union.
About ADITEC
ADITEC is a multinational collaborative research programme that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Scientists from 13 countries and 42 research partners collaborate in the ADITEC project.
ADITEC comprises some of the most competitive European research groups from universities, research institutions and biotech companies together with top US groups on systems biology and adjuvants. Different aspects of vaccination, from basic research, new technologies to clinical trials and public health, are covered. Details can be found on the project website www.aditecproject.eu
Significant and strong immunogenicity measured with a standardized hemagglutination inhibition (HI) test was achieved and seroconversion occurred in the primates. Non-human primates are an in vivo model closest to humans. Results usually seen in this model are considered indicative of efficacy expected in clinical trials in humans. Results seen by CILIAN in primates confirm results already seen in a number of other pre-clinical studies conducted with CiFlu®. This is further evidence that CiFlu® is an effective, fully recombinant, none egg-based sub-unit flu vaccine without adjuvant or other impurities.
CiFlu® is manufactured using CILIAN’s proprietary CIPEX protein expression system. CIPEX uses a single cell organism, Tetrahymena thermophila. This expression system produces a very robust protein in a safe, fast and significantly less expensive process as compared to egg-based systems.
About CILIAN
CILIAN AG is a privately owned biotechnology company located in Münster, Germany. CILIAN develops recombinant sub-unit vaccines; therapeutic enzymes for the treatment of pancreatic insufficiency; and ADCC monoclonal antibodies against cancer utilizing its proprietary protein expression system CIPEX. For more information on CILIAN AG, please go to www.cilian.com.
CILIAN is an affiliated member of ADITEC and participates in its advanced immunization technologies research program. CiFlu® is a registered trademark of CILIAN AG in the European Union.
About ADITEC
ADITEC is a multinational collaborative research programme that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Scientists from 13 countries and 42 research partners collaborate in the ADITEC project.
ADITEC comprises some of the most competitive European research groups from universities, research institutions and biotech companies together with top US groups on systems biology and adjuvants. Different aspects of vaccination, from basic research, new technologies to clinical trials and public health, are covered. Details can be found on the project website www.aditecproject.eu
